The decrease in CLL progression observed by Yigit in xenografted SCID mice model after the administration of anti-SLAMF6 confirmed the implication of this receptor in CLL pathophysiology. This evidence concerns the gene SLAMF6 and B-cell chronic lymphocytic leukemia.